List view / Grid view
Over the past 30 years, one strategy the pharmaceutical industry has adopted in the drug discovery process has been to “fail early, fail often”.1,2 As most molecules in the early stages of drug discovery will have sub-optimal characteristics, significant modification is necessary to improve their properties.
Autophagy is an important process to maintain cellular homeostasis and function.1 Basal levels of autophagy are essential for most cells to remove unwanted protein aggregates and damaged organelles in order to prevent diseases.2 However, sometimes cells are unable to maintain physiological stability as a consequence of altered autophagy, which leads…
This article compares and contrasts a commonly used cell viability assay in manual and automated fashion and provides exemplar data from each scenario.
In this issue: how lab automation has accelerated pharmaceutical research by simplifying operations, reducing manual tasks and increasing the efficiency, quality and reproducibility of results.
Neglected tropical diseases (NTD) affect more than one billion people and new targets and drugs are needed to tackle these infections. The multi-disciplinary NMTrypI consortium has identified a number of different compound classes which could be effective against these diseases. This article reviews some of these compounds...
A significant amount of selectivity and potency data originating from screening of drug targets is generated each year and deposited in public databases. This can be exploited to accelerate drug discovery, in particular, for a variety of repurposing activities...
Drugs exert therapeutically meaningful effects if they bind with appropriate selectively and potency to their respective targets. Although many of the assay techniques employed in early-stage drug discovery provide evidence that a drug is acting upon the target under investigation, this is often indirect and the site of action and…
The screening of drug targets against compound libraries is now a mature and validated approach to identifying the chemical starting points of drugs...
Included in this Screening In-Depth Focus: Phenotypic and target-based screening; Killing cancer cells using clinical drug resistance; Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool...
20 September 2016 | By Drug Target Review
In this Hit-To-Lead In-Depth Focus: Hit-to-lead in drug discovery; Zebrafish early-life stages as neurological screening and detection tools...
Featured in this Stem Cells In-depth Focus: Translating stem cell biology into drug discovery; Mechanism-informed phenotypic screening – the missing link for cancer drug discovery; Analysis of human stem cell interactions at the single-cell resolution...
Preview of the upcoming foreword in our April issue, written by Sheraz Gul, Vice President and Head of Biology at Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, Germany...
Sheraz Gul, Head of Biology at Fraunhofer-IME SP, provides an in-depth review of the Cell-Based Assays for Screening workshop which took place in December 2014...
Editor Caroline Richards talks about the editorial board members who have influenced the content coming up in the latest issue of Drug Target Review, available in April 2015...
6 February 2015 | By
Head of Drug Discovery at the Fraunhofer Institute for Molecular Biology and Applied Ecology
